Short answer
RxSight, Inc. (RXST) filed its Q1 2026 10-Q quarterly report on May 6, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $31M (down 18.5% year over year) with net income of −$16M.
Q1 2026 key financials · XBRL
- Revenue
- $31M
- −18.5% YoY
- Net income
- −$16M
- −93.9% YoY
- Operating margin
- -57.7%
- Gross margin
- 76.1%
- EPS (diluted)
- −$0.38
- −90.0% YoY
Source: XBRL data from the RxSight, Inc. (RXST) Q1 2026 10-Q on SEC EDGAR. USD.
RxSight, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $30.9M, down 18.5% YoY from $37.9M, primarily due to lower LDD volumes
- Gross margin 76.1% vs 74.8% YoY, driven by favorable LAL product mix
- LAL sales $27.0M vs $27.2M; LDD sales $2.4M vs $9.4M, weakest product line
- Cash, equivalents and short-term investments $217.9M; operating cash outflow $10.9M vs $8.8M YoY
- Outlook: commercial realignment expected to support growth; continued losses and negative operating cash flows anticipated near term
Risk Factors
- Sales decline in 2025 and Q1 2026 triggered commercial reorganization into a Customer Success Organization
- QMSR became effective February 2026, requiring compliant manufacturing processes and potential additional regulatory work
- July 2025 putative securities class action remains pending in the Central District of California
- Single-bank concentration: all cash, equivalents and short-term investments held at one institution, partly above FDIC limits
- Liquidity risk: $217.9 million in cash, equivalents and short-term investments as of March 31, 2026, supporting at least 12 months of needs
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other RxSight, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.